This content is only available within our institutional offering.

05 Jun 2023
Tristel: FDA approval — a significant inflection point

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Tristel: FDA approval — a significant inflection point
Tristel Plc (TSTL:LON) | 355 10.7 0.9% | Mkt Cap: 169.4m
- Published:
05 Jun 2023 -
Author:
Paul Cuddon | Kane Slutzkin -
Pages:
4 -